Acute renal vein thrombosis, oral contraceptive use, and hyperhomocysteinemia

Mayo Clinic Proceedings

Volumn 76, Issue 2, 2001, Pages 212-214

  Chan, Howard H W ^a   Douketis, James D ^b   Nowaczyk, Malgorzata J M ^c  

^a Department of Medicine ^*

^b MCMASTER UNIVERSITY   (Canada)

^c ST JOSEPH S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

COBALAMIN DERIVATIVE; CYANOCOBALAMIN; CYSTATHIONINE BETA SYNTHASE; FOLIC ACID; HEPARIN; HOMOCYSTEINE; METHIONINE; ORAL CONTRACEPTIVE AGENT; PROPIONIC ACID DERIVATIVE; PYRIDOXINE; WARFARIN;

ABDOMINAL PAIN; ADULT; ARTICLE; CASE REPORT; DISEASE ASSOCIATION; DRUG USE; ENZYME POLYMORPHISM; FEMALE; HEMATURIA; HUMAN; HYPERHOMOCYSTEINEMIA; KIDNEY VEIN THROMBOSIS; ORAL CONTRACEPTION; RADIODIAGNOSIS; RISK FACTOR; THROMBOEMBOLISM;

EID: 0035146924     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/76.2.212     Document Type: Article

References (29)

1. Zucchelli P. Renal vein thrombosis. Nephrol Dial Transplant. 1992;7(suppll):105-108.
2. du Buf-Vereijken PW, Hilbrands LB, Wetzels JF. Partial renal vein thrombosis in a kidney transplant: management by streptokinase and heparin. Nephrol Dial Transplant. 1998; 13:499-502.
3. Stein JH, McBride PE. Hyperhomocysteinemia and atherosclerotic vascular disease: pathophysiology, screening, and treatment. Arch Intern Med. 1998;158:1301-1306.
4. Douketis JD, Ginsberg JS, Holbrook A, Crowther M, Duku EK, Burrows RF. A réévaluation of the risk for venous thromboembolism with the use of oral contraceptives and hormone replacement therapy. Arch Intern Med. 1997; 157:1522-1530.
5. Kluijtmans LA, van den Heuvel LP, Boers GH, et al. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet. 1996;58:35-41.
6. Uhlendorf BW, Mudd SH. Cystathionine synthase in tissue culture derived from human skin: enzyme defect in homocystinuria. Science. 1968; 160:1007-1009.
7. Byck S, Rosenblatt DS. Metabolic cooperation among cell lines from patients with inborn errors of vitamin B12 metabolism: differential response of cblC and cblD. Clin Invest Med. 1991; 14: 153-159.
8. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995; 10:111 -113.
9. Pohl M, Zimmerhackl LB, Heinen F, Sutor AH, Schneppenheim R, Brandis M. Bilateral renal vein thrombosis and venous sinus thrombosis in a neonate with factor V mutation (FV Leiden). J Pediatr. 1998; 132:159-161.
10. Cosgriff TM, Bishop DT, Hershgold EJ, et al. Familial antithrombin III deficiency: its natural history, genetics, diagnosis and treatment. Medicine (Baltimore). 1983;62:209-220.
11. Ko WS, Lim PS, Sung YP. Renal vein thrombosis as first clinical manifestation of the primary antiphospholipid syndrome. Nephrol Dial Transplant. 1995 ; 10:1929-1931.
12. Rogers PC, Suva MP, Carter JE, Wadsworth LD. Renal vein thrombosis and response to therapy in a newborn with protein C deficiency. EurJ Pediatr. 1989; 149:124-125.
13. Farmer RDT, Preston TD. The risk of venous thromboembolism associated with low oestrogen oral contraceptives. J Obstet Gynaecol. 1995; 15:195-200.
14. Gerstman BB, Piper JM, Tomita DK, Ferguson WJ, Stadel BV, Lundin FE. Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol. 1991; 133:32-37.
15. Leclerc JR, Gent M, Hirsh J, Geerts WH, Ginsberg JS, Canadian Collaborative Group. The incidence of symptomatic venous thromboembolism during and after prophylaxis with enoxaparin: a multi-institutional cohort study of patients who underwent hip or knee arthroplasty. Arch Intern Med. 1998; 158:873-878.
16. den Heijer M, Koster T, Blom HJ, et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med. 1996;334: 759-762.
17. Fermo I, Vigano D'Angelo S, Paroni R, Mazzola G, Calori G, D'Angelo A. Prevalence of moderate hyperhomocysteinemia in patients with early-onset venous and arterial occlusive disease. Ann Intern Med. 1995;123:747-753.
18. den Heijer M, Blom HJ, Gerrits WB, et al. Is hyperhomocysteinaemia a risk factor for recurrent venous thrombosis? Lancet. 1995; 345:882-885.
19. Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oralcontraceptive users who are carriers of factor V Leiden mutation. Lancet. 1994;344:1453-1457.
20. Martinelli I, Sacchi E, Landi G, Taioli E, Duca F, Mannucci PM. High risk of cerebral-vein thrombosis in carriers of a prothrombingene mutation and in users of oral contraceptives. N Engl J Med. 1998;338:1793-1797.
21. Rintelen C, Mannhalter C, Ireland H, et al. Oral contraceptives enhance the risk of clinical manifestations of venous thrombosis at a young age in females homozygous for factor V Leiden. Br J Haematol. 1996;93:487-490.
22. Bloemenkamp KW, Rosendaal FR, Heimerhorst FM, Vandenbroucke JP. Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects. Arch Intern Med. 2000; 160:49-52.
23. Pabinger I, Schneider B, Gesellschaft fur Thrombose- und Hamostaseforschung (GTH) Study Group on Natural Inhibitors. Thrombotic risk in hereditary antithrombin III, protein C, or protein S deficiency: a cooperative, retrospective study. Arterioscler Thromb VascBiol. 1996; 16:742-748.
24. Tabernero MD, Tomas JF, Alberca I, Orfao A, Lopez Borrasca A, Vincente V. Incidence and clinical characteristics of hereditary disorders associated with venous thrombosis. Am J Hematol. 1991;36:249-254.
25. Guttormsen AB, Ueland PM, Nesthus I, et al. Determinants and vitamin responsiveness of intermediate hyperhomocysteinemia (>40 micromol/liter): the Hordaland Homocysteine Study. J Clin Invest. 1996;98:2174-2183.
26. Smith JL, Goldsmith GA, Lawrence JD. Effects of oral contraceptive steroids on vitamin and lipid levels in serum. Am J Clin Nutr. 1975;28:371-376.
27. Hjelt K, Brynskov J, Hippe E, Lundstrom P, Munck O. Oral contraceptives and the cobalamin (vitamin B12) metabolism. Acta Obstet Gynecol Scand. 1985;64:59-63.
28. van der Mooren MJ, Demacker PN, Blom HJ, de Rijke YB, Rolland R. The effect of sequential three-monthly hormone replacement therapy on several cardiovascular risk estimators in postmenopausal women. Fertil Steril. 1997;67:67-73.
29. Berger PB, Herrmann RR, Dumesic DA. The effect of estrogen replacement therapy on total plasma homocysteine in healthy postmenopausal women. Mayo Clin Proc. 2000;75:18-23.